Overview

Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Status:
Not yet recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This study will determine the tissue penetration of a broad-spectrum orally bioavailable carbapenem, tebipenem pivoxil hydrobromide (SPR994) (Spero Therapeutics, Inc.), into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.

Phase:

Phase 1

Details

Lead Sponsor:

Hartford Hospital

Collaborator:

Spero Therapeutics Inc